嵌合抗原受体T细胞治疗多发性骨髓瘤研究进展
Progress of chimeric antigen receptor T-cell therapy for multiple myeloma
马静远 1郝牧1
作者信息
- 1. 中国医学科学院血液病医院(中国医学科学院血液学研究所)实验血液学国家重点实验室 国家血液系统疾病临床医学研究中心 细胞生态海河实验室,天津 300020;天津医学健康研究院,天津 301600
- 折叠
摘要
多发性骨髓瘤(MM)是第二常见的血液系统恶性肿瘤.近年来,蛋白酶体抑制剂、免疫调节药物等新一代药物显著改善了MM患者的预后,中位生存期延长至3～6年.同时,嵌合抗原受体T细胞(CAR-T)免疫疗法在治疗复发难治MM方面取得了巨大进展,但高复发率和较短的缓解时间仍然是CAR-T治疗亟待解决的问题.需探究影响CAR-T疗效和安全性的因素,优化CAR-T治疗策略.文章对2023年第65届美国血液学会(ASH)年会报道的关于CAR-T治疗MM的前沿进展进行总结.
Abstract
Multiple myeloma(MM)is the second most common hematologic malignancy.In recent years,the advent of a new generation of drugs including proteasome inhibitors and immunomodulatory drugs has significantly improved the prognosis of MM patients,extending the median survival to 3-6 years.Meanwhile,chimeric antigen receptor T-cell(CAR-T)immunotherapy has made great progress in treating relapsed/refractory MM,but the high relapse rate and short remission duration are still challenges for CAR-T therapy.Therefore,it is imperative to explore factors affecting the efficacy and safety of CAR-T therapy and optimize the treatment strategies.This article reviews the recent advances in CAR-T therapy for MM reported at the 65th American Society of Hematology(ASH)Annual Meeting in 2023.
关键词
多发性骨髓瘤/嵌合抗原受体T细胞/分子靶向治疗/治疗结果Key words
Multiple myeloma/Chimeric antigen receptor T-cell/Molecular targeted therapy/Treatment outcome引用本文复制引用
出版年
2024
NETL
NSTL
万方数据